2
FEBRUARY 2024
Oncimmune Holdings plc
("Oncimmune" or the
"Company")
Notice of Annual General
Meeting
Oncimmune Holdings plc (AIM: ONC.L), a leading
autoantibody profiling company to the pharmaceutical and
biotechnology industry enabling precision medicine, today gives
notice that its Annual General Meeting ("AGM") will be held at
10:00am GMT on 26 February 2024 at the offices of Singer Capital
Markets, 1 Bartholomew Lane, London, EC2N 2AX.
The Notice of AGM has been sent to shareholders
and can also be viewed on the "Investors" section of the Company's
website at www.oncimmune.com.
The audit process for the Company's financial
results for the 12 months ended 31 August 2023 ("FY2023") is
continuing in the ordinary course and the Company expects its
annual report, including the financial statements for FY2023, to be
published by the end of February 2024 and for this to be laid
before a separate general meeting in March 2024.
For further
information:
Oncimmune
Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated
Adviser and Broker)
Philip Davies, Harry Gooden, James
Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan
Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK,
with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com